Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver
Completed · Phase 2
Conditions studied: Colorectal Cancer, Metastatic Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells. PURPOSE: This phase II trial is studying how well isolated hepatic perfusion with melphalan works in treating patients with unresectable colorectal cancer that has metastasized to the liver.
Key facts
- Study ID
- NCT00089401
- Run by
- National Institutes of Health Clinical Center (CC)
- People needed
- 8
- Starts
- 2004-07-01
- Expected to finish
- 2008-03-01
- Last updated by the study team
- 2012-05-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.